Clinical Trial Search

Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale

Primary: Percentage of Patients Remaining Alive and Progression-free at 6 Months as Per RECIST 1.1 After the Day of Randomisation (6-month Non-progression Rate). — 84.8; 45.0…

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Immune Response Rate — 0.29; 0.67 proportion of participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Cohort 1: Overall Survival — 13.4; 11.9; 8.1 months

Primary: Phase I: Maximum Tolerated Dose (MTD) of Trabectedin When Administered in Association With CP. — 0.50 mg/m^2

Primary: Number of Participants With Enhanced T Lymphocyte Immune Response Specific for Soft Tissue Sarcoma Tumor Associated Antigens(STS-TAAs) — 2; 5 participants

Primary: Progression Free Survival at 12 Weeks — 66; 57.2 percentage of particpants

Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants

Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants

Primary: Overall Response Rate (ORR) — 9; 3; 6 participants

Primary: Part 1: Photosensitizer Uptake and Conversion to Protoporphyrin IX — 304 Densitometry units/micrometer squared — p=0.0001

Primary: Local Disease Control Assessed by Physical Examination — 0 Participants

Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001

Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants

Primary: Immunohistochemical Immunoreactive Score Results After 4 Weeks of Sirolimus Compared to Control Specimens — 5.22; 7.44; 4.47; 9.39 score on a scale — p=0.63

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030

Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion

Primary: Physician's DPN Lesions Assessment — -0.75; -1.38; -0.92 score on a scale (PLA)

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events